Solara Active Pharma Sciences Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Solara Active Pharma Sciences Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 23% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 93% of Healthcare companies in India.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 21% of its market value (net debt). Lower than 91% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
3.5×Over the last 3 years its own operating cash covered its investment spending (capex) 3.5 times.
Higher than 84% of Healthcare companies in India.
Cash Locked Ratio
₹33For every ₹100 of sales, ₹33 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹56 tied up three years earlier.
More money tied up than 68% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 84% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -4% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-4% / -20%In 3 years sales changed by -4% while total assets changed by -20%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.3×Debt due within a year is covered 0.3 times by its yearly operating cash.
Lower than 80% of Healthcare companies in India.
Cash Cushion Ratio
−21%Debt, after subtracting cash, equals 21% of its market value (net debt).
Lower than 91% of Healthcare companies in India.
Tangible Assets Ratio
83%Of every ₹100 the company owns, ₹83 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 79% of Healthcare companies in India.
Tangible Net Worth Ratio
69%Of every ₹100 of net worth, ₹69 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 80% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Solara Active Pharma Sciences Limited made a loss over the last year. Solara Active Pharma Sciences Limited owes ₹0.46 for every ₹1 it owns. Solara Active Pharma Sciences Limited made a loss in the year to Mar 2026, after a profit the year before.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
LossSolara Active Pharma Sciences Limited made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.35The share price is 2.35 times Solara Active Pharma Sciences Limited's book value per share, lower than 78% of Healthcare companies in India.
Market cap
₹2,940 CrThe total market value of all of Solara Active Pharma Sciences Limited's shares at today's price (share price × number of shares), smaller than 58% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹1,253 CrWhat Solara Active Pharma Sciences Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹260.57Net worth divided by the number of shares. The share price of ₹611.55 is 2.3 times this, which is the P/B above.
Return on equity (ROE)
-0.2%Solara Active Pharma Sciences Limited lost 0.2% of its shareholders' money over the last year, lower than 93% of Healthcare companies in India.
Owes vs Owns
0.46×Solara Active Pharma Sciences Limited owes ₹0.46 for every ₹1 it owns (low), higher than 74% of Healthcare companies in India.
Dividend yield
NoneSolara Active Pharma Sciences Limited does not currently pay a dividend.
Revenue growth
+7%Revenue rose 7% in the year to Mar 2026, and shrank 1% a year on average over 3 years.
Profit growth
LossSolara Active Pharma Sciences Limited made a loss in the year to Mar 2026, after a profit the year before.
Profit margin
-0.6%Solara Active Pharma Sciences Limited lost ₹1 for every ₹100 of revenue.
Interest cover
1.1×Solara Active Pharma Sciences Limited's operating profit covered its interest costs 1.1 times in the year to Mar 2026.
Cash vs debt
Net debtSolara Active Pharma Sciences Limited had ₹633 Cr more debt than cash (net debt) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Solara Active Pharma Sciences Limited: ₹2,940 Cr ÷ ₹1,253 Cr (31 Mar 2026) = 2.3.
What is Solara Active Pharma Sciences Limited's return on equity?
Solara Active Pharma Sciences Limited lost 0.2% of its shareholders' money over the last year, lower than 93% of Healthcare companies in India.
How much does Solara Active Pharma Sciences Limited owe compared with what it owns?
Solara Active Pharma Sciences Limited owes ₹0.46 for every ₹1 it owns (low), higher than 74% of Healthcare companies in India.
Does Solara Active Pharma Sciences Limited pay a dividend?
No. Solara Active Pharma Sciences Limited does not currently pay a dividend.
Is Solara Active Pharma Sciences Limited's revenue growing?
Revenue rose 7% in the year to Mar 2026, and shrank 1% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.